Low-Risk Endometrial Carcinoma: Assessment of a Treatment Policy Based on Tumor Ploidy and Identification of Additional Prognostic Indicators
- 1 May 1999
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 73 (2) , 191-195
- https://doi.org/10.1006/gyno.1999.5365
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- p53 overexpression in advanced-stage endometrial adenocarcinomaAmerican Journal of Obstetrics and Gynecology, 1996
- Estrogen Receptor Immunocytochemistry in Endometrial Carcinoma: A Prognostic Marker for SurvivalGynecologic Oncology, 1996
- Endometrial Neoplasia: Prognostic Significance of Ploidy StatusClinical Obstetrics and Gynecology, 1996
- p53 Protein Overexpression in Early Stage Endometrial CancerGynecologic Oncology, 1996
- p53 as a Prognostic Indicator in Endometrial CancerGynecologic Oncology, 1996
- Clinicopathological characteristics of p53 overexpression in endometrial cancersInternational Journal of Cancer, 1994
- Prognostic Value of DNA Ploidy and S-Phase Fraction in Endometrial Cancer Stage I and II: A Prospective 5-Year Survival StudyGynecologic Oncology, 1994
- Evaluation of DNA Ploidy in Endometrial CancerGynecologic Oncology, 1993
- Flow cytometric studies of ploidy and proliferative indices in the Yorkshire trial of adjuvant progestogen treatment of endometrial cancerBJOG: An International Journal of Obstetrics and Gynaecology, 1993
- Prognostic value of pathologic features and DNA analysis in endometrial carcinomaGynecologic Oncology, 1990